Seocalcitol | CAS:134404-52-7

Chemscene社は、高品質な低分子化合物を提供しているメーカーです。
Chemscene社のSeocalcitol(CAS:134404-52-7)をご紹介します。

※本製品は研究用です。研究用以外には使用できません。

Name:Seocalcitol; EB 1089
Cat. No. :CS-0398
CAS No. :134404-52-7
Formula:C30H46O3
M. Wt. : 454.68
Solubility:10 mM in DMSO

Seocalcitol is a vitamin D analog, binds vitamin D receptor protein from human osteosarcoma MG-63 cells with Kd of 0.27 nM. IC50 & Target: Kd: 0.27 nM (vitamin D receptor)[1]In Vitro: Seocalcitol (EB 1089) is a stimulators of osteoclast recruitment in murine bone marrow cultures, with EC50 at 0.1 nM. Seocalcitol stimulates bone resorption with an estimated EC50 at 0.03 nM[1]. Seocalcitol (EB 1089) elicites a dose-dependent induction of 24-hydroxylase mRNA in the kidney (EC50=0.4±0.13). In the kidney, Kd values for Seocalcitol is 0.48±0.04 nM. However, in the intestine, the Kd for Seocalcitol is 1.43±0.19 nM)[2]. Seocalcitol (0.1-10 nM) induces cell differentiation in a dosedependent manner. A higher differentiating activity is observed for 1 nM Seocalcitol (EB 1089) than for 1 nM VD3.In Vivo: Seocalcitol (EB1089), a synthetic vitamin D analog, exhibits reduced hypercalcemic activity relative to 1,25(OH)2VD3. In another study, long-term intraperitoneal (IP) administration of Seocalcitol at a dose of 0.5 μg/kg body weight every other day in C3H/Sy mice exertes a very strong inhibitory effect on hepatocellular carcinoma (HCC) development[4]. Seocalcitol (EB 1089) is administered daily to postnatal rats from 4 to 12 days of age (P4 to P12) by intraperitoneal injection at either 0.38 or 1.25 μg/kg body weight (BW)/day. Only the highest dose of Seocalcitol (1.25 μg/kg BW) causes a significant reduction in weight gain when administered alone or in conjunction with Dexamethasone, all-trans retinoic acid (RA), or retinoic acid[5].

Bondza-Kibangou P, et al. Antioxidants and doxorubicin supplementation to modulate CD14 expression and oxidative stress induced by vitamin D3 and seocalcitol in HL60 cells. Oncol Rep. 2007 Dec;18(6):1513-9. Wiberg K, et al. Studies on two new vitamin D analogs, EB 1089 and KH 1060: effects on bone resorption and osteoclast recruitment in vitro. Bone. 1995 Oct;17(4):391-5. Ghous Z, et al. Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. Anticancer Res. 2008 Nov-Dec;28(6A):3757-61. Roy S, et al. Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase. J Bone Miner Res. 1995 Dec;10(12):1951-9. Ormerod AK, et al. The calcitriol analogue EB1089 impairs alveolarization and induces localized regions of increased fibroblast density in neonatal rat lung. Exp Lung Res. 2008 May;34(4):155-82.